Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocotrienol Against the Progression of End Stage Liver Disease
NCT02581085Phase 2Completed
- Start
- Nov 2019
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in liver disease, Nonalcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) (2 arms). Primary endpoint: Model for End-Stage Liver Disease at 3 years. Started Nov 2019; status: completed.
02
Conditions
liver diseaseNonalcoholic steatohepatitis (NASH)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02581085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581085.